Therapeutic Options for Progressive GIST

Video

Patients with gastrointestinal stromal tumors (GISTs) typically receive 400 mg of imatinib as maintenance therapy, provided they are responding and tolerating initial therapy. Treatment holidays are not taken in this setting, notes Syma Iqbal, MD, since studies have shown that outcomes are worse when imatinib is temporarily discontinued. This is potentially due to a tumor flare effect, she adds, making appropriate radiologic assessment important.

The imatinib dose is typically increased from 400 mg to 800 mg for patients with progressive GIST. Approximately one third of patients may achieve disease stability from this strategy, comments Iqbal. Individuals who cannot tolerate 800 mg or have disease progression while on 800 mg should be switched to another tyrosine kinase inhibitor (TKI), such as sunitinib, which targets vascular endothelial growth factor. Regorafenib, a multi-targeted TKI, is approved in the third-line setting.

Individuals who have failed three lines of therapy should be evaluated at a high-volume sarcoma center that treats GISTs on a routine basis, since many of these centers offer clinical trials that may improve patient outcomes, states Anthony P. Conley, MD. Other available TKIs that have been approved for other indications include dasatinib, nilotinib, sorafenib, pazopanib, and axitinib. These agents may be used in GIST treatment in certain off-label situations, says Conley.

Related Videos
In this third episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Joachim G. J. V. Aerts, MD, PhD
Nathaniel Myall, MD
Martin Cannon, PhD, professor, Department of Microbiology, University of Arkansas for Medical Sciences College of Medicine
Pedro Barata, MD, MSc
In this fourth episode of OncChats: Examining LIFU–Aided Liquid Biopsy in Glioblastoma, Manmeet Singh Ahluwalia, MD, and Michael W. McDermott, MD, discuss the key objectives of the phase 3 LIMITLESS study (NCT05317858) examining low-intensity focused ultrasound with immunotherapy and chemotherapy in patients with lung cancer and brain metastases.
Brian Mitzman, MD, FACS, FCCP
Yvonne Chao, MD, PhD